Physician profile
Asia Mohsin
NPI 1760622401
$3,039.15
in general payments reported to CMS, 2019-2025
33 companies · $504 in 2025
The $504 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $360 · 2021: $470 · 2022: $602 · 2023: $499 · 2024: $309 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.46 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.33 | 2020-2023 | |
| Astellas Pharma US INC | $350.26 | 2022-2025 | Veozah |
| Millicent US INC | $255.66 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Mayne Pharma Commercial LLC | $178.17 | 2021-2023 | |
| Hologic Sales and Service, LLC | $151.88 | 2019-2023 | Novasure |
| Sumitomo Pharma America, INC. | $126.61 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $117.50 | 2021-2022 | |
| Exeltis, USA INC. | $111.66 | 2021-2025 | Slynd |
| Currax Pharmaceuticals LLC | $90.96 | 2020-2024 | Contrave, Onzetra Xsail |
| Shield Therapeutics INC | $89.47 | 2023-2025 | Accrufer |
| Avion Pharmaceuticals | $89.26 | 2021-2023 | Divigel |
| Neurocrine Biosciences, INC. | $87.25 | 2019 | |
| Novo Nordisk INC | $73.67 | 2021-2025 | Wegovy |
| Lupin INC. | $62.95 | 2019-2020 | |
| Pfizer INC. | $58.75 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $55.25 | 2019 | |
| Axsome Therapeutics, INC. | $33.17 | 2025 | Auvelity |
| Scynexis, INC. | $32.56 | 2022 | |
| Aspira Women'S Health INC | $31.84 | 2020-2024 | Ova1 |
| Takeda Pharmaceuticals U.S.A., INC. | $31.25 | 2019 | |
| Daiichi Sankyo INC. | $26.81 | 2023 | Injectafer |
| Medtronic USA, INC. | $26.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.33 | 2025 | |
| Organon LLC | $24.00 | 2021 | |
| Evofem Biosciences, INC. | $22.64 | 2022 | |
| Vertical Pharmaceuticals, LLC | $22.49 | 2019 | |
| Merck Sharp & Dohme LLC | $21.43 | 2020 | |
| Mylan Pharmaceuticals INC. | $21.09 | 2022 | |
| Becton, Dickinson and Company | $20.65 | 2020 | |
| Medicem INC. | $18.00 | 2021 | |
| Therapeuticsmd, INC. | $15.36 | 2020 | |
| Coopersurgical, INC. | $15.31 | 2020 | |
| Acessa Health INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asia Mohsin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.